Additional Table 1. Distribution of isolated strain susceptibility for antimicrobials other than β-lactams

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CCs | CHL | | AZM | | | TET | | | SXT | | | LVX | | Total | Related PMEN clones |
| S (n) | R (n) | S (n) | I (n) | R (n) | S (n) | I (n) | R (n) | S (n) | I (n) | R (n) | S (n) | R (n) |
| 180 | 13 | 37 | 4 |  | 46 | 6 |  | 44 | 47 | 2 | 1 | 50 |  | 50 | Netherlands3-31 |
| 99 | 12 | 2 |  |  | 14 |  |  | 14 | 12 | 1 | 1 | 14 |  | 14 |  |
| 236 | 12 |  | 1 |  | 11 |  |  | 12 | 1 |  | 11 | 12 |  | 12 | Taiwan19F-14 |
| 433 | 6 | 3 | 2 |  | 7 | 6 |  | 3 | 8 | 1 |  | 9 |  | 9 |  |
| 199 | 7 | 1 | 1 |  | 7 | 1 |  | 7 | 5 |  | 3 | 8 |  | 8 | Netherlands15B-37 |
| 63 | 8 |  |  |  | 8 |  |  | 8 | 7 |  | 1 | 8 |  | 8 | Sweden15A-25 |
| 2755 | 8 |  |  |  | 8 | 1 |  | 7 |  |  | 8 | 8 |  | 8 |  |
| 242 | 7 |  |  |  | 7 |  |  | 7 |  | 5 | 2 | 7 |  | 7 | Taiwan23F-15 |
| 3111 | 6 | 1 |  | 1 | 6 |  |  | 7 | 6 |  | 1 | 7 |  | 7 |  |
| 338 | 6 |  |  |  | 6 |  |  | 6 | 5 |  | 1 | 6 |  | 6 | Colombia23F-26 |
| 280 | 5 |  | 2 |  | 3 | 5 |  |  | 4 |  | 1 | 5 |  | 5 |  |
| 15 | 5 |  |  |  | 5 |  |  | 5 | 5 |  |  | 5 |  | 5 | SLV England14-9 |
| 5236 | 4 | 1 |  |  | 5 |  |  | 5 | 5 |  |  | 5 |  | 5 |  |
| 558 | 5 |  | 1 |  | 4 | 2 |  | 3 | 4 |  | 1 | 5 |  | 5 | SLV Utah35B-24 |
| 2331 | 3 | 2 | 1 |  | 4 | 2 |  | 3 | 3 |  | 2 | 4 | 1 | 5 |  |
| 5241 | 4 |  | 3 |  | 1 | 3 |  | 1 |  | 1 | 3 | 4 |  | 4 |  |
| 62 | 4 |  |  |  | 4 | 3 |  | 1 |  | 1 | 3 | 4 |  | 4 |  |
| 2756 | 4 |  | 1 |  | 3 | 2 |  | 2 |  | 1 | 3 | 4 |  | 4 |  |
| 90 | 2 | 1 |  |  | 3 |  |  | 3 |  |  | 3 | 3 |  | 3 | Spain6B-2 |
| Singleton | 2 | 1 |  |  | 3 |  |  | 3 | 2 | 1 |  | 3 |  | 3 |  |
| 2924 | 3 |  |  |  | 3 |  |  | 3 | 2 |  | 1 | 3 |  | 3 |  |
| 2572 | 3 |  |  |  | 3 |  |  | 3 |  | 2 | 1 | 3 |  | 3 |  |
| 81 |  | 3 |  |  | 3 |  |  | 3 |  | 1 | 2 | 3 |  | 3 | Spain23F-1 |
| 2923 | 3 |  | 1 |  | 2 | 1 |  | 2 |  | 1 | 2 | 3 |  | 3 |  |
| 5832 | 2 |  | 1 |  | 1 | 1 |  | 1 |  |  | 2 | 2 |  | 2 |  |
| 2758 | 2 |  |  |  | 2 |  |  | 2 |  |  | 2 | 2 |  | 2 |  |
| 5238 |  | 1 |  |  | 1 |  |  | 1 |  | 1 |  | 1 |  | 1 |  |
| 343 |  | 1 |  |  | 1 |  |  | 1 |  |  | 1 | 1 |  | 1 |  |
| 246 | 1 |  |  |  | 1 |  |  | 1 | 1 |  |  | 1 |  | 1 |  |
| 7494 | 1 |  |  |  | 1 |  |  | 1 | 1 |  |  | 1 |  | 1 |  |
| 902 | 1 |  |  |  | 1 |  | 1 |  |  |  | 1 | 1 |  | 1 |  |
| 3113 | 1 |  |  |  | 1 |  |  | 1 |  |  | 1 | 1 |  | 1 |  |
| 156 | 1 |  |  |  | 1 |  |  | 1 |  |  | 1 | 1 |  | 1 | Spain9V-3 |
| 3116 | 1 |  | 1 |  |  | 1 |  |  |  |  | 1 | 1 |  | 1 |  |
| 191 | 1 |  |  |  | 1 |  |  | 1 | 1 |  |  | 1 |  | 1 | Netherlands7F-39 |
| 3117 | 1 |  | 1 |  |  | 1 |  |  | 1 |  |  | 1 |  | 1 |  |
| 6433 |  | 1 |  |  | 1 |  |  | 1 | 1 |  |  | 1 |  | 1 |  |
| 3594 |  | 1 |  |  | 1 |  |  | 1 |  |  | 1 | 1 |  | 1 |  |
| 7800 | 1 |  | 1 |  |  | 1 |  |  |  | 1 |  | 1 |  | 1 |  |
| 1591 |  | 1 |  |  | 1 |  |  | 1 |  |  | 1 | 1 |  | 1 |  |
| 4745 | 1 |  |  |  | 1 |  |  | 1 |  |  | 1 | 1 |  | 1 |  |
| 5233 | 1 |  |  |  | 1 |  |  | 1 | 1 |  |  | 1 |  | 1 |  |
| Total | 147 | 57 | 21 | 1 | 182 | 36 | 1 | 167 | 122 | 19 | 63 | 203 | 1 | 204 |  |

Susceptibility interpretation was based on CLSI 2014, CC: clonal complex, CHL: chloramphenicol, AZM: azithromycin, TET: tetracycline, SXT: sulfamethoxazole and trimethoprim, LVX: levofloxacin, S; susceptible, I: intermediate, R: resistant, PMEN: Pneumococcal Molecular Epidemiology Network, SLV: single locus variant